Academic literature on the topic 'Vaccines industry Australia'

The Therapeutic Goods Administration (TGA) is responsible for the licensing of vaccines used in Australia. This includes pre-market evaluation aspects (such as assessing the quality, efficacy and safety of vaccines) and post-market aspects (such as batch release testing and the monitoring of adverse reactions). For inter-pandemic and pandemic influenza vaccines, TGA is also involved in the selection of appropriate vaccine viruses and the calibration and supply of reagents for the production of influenza vaccines. Together with industry, TGA has a responsibility to ensure that all regulatory and good manufacturing requirements (GMP) are met to ensure vaccine safety and efficacy.

Critical criminology repeatedly has drawn attention to the state-corporate nexus as a site of corruption and other forms of criminality, a scenario exacerbated by the intensification of neoliberalism in areas such as health. The state-pharmaceutical relationship, which increasingly influences health policy, is no exception. That is especially so when pharmaceutical products such as vaccines, a burgeoning sector of the industry, are mandated in direct violation of the principle of informed consent. Such policies have provoked suspicion and dissent as critics question the integrity of the state-pharma alliance and its impact on vaccine safety. However, rather than encouraging open debate, draconian modes of governance have been implemented to repress and silence any form of criticism, thereby protecting the activities of the state and pharmaceutical industry from independent scrutiny. The article examines this relationship in the context of recent legislation in Australia to intensify its mandatory regime around vaccines. It argues that attempts to undermine freedom of speech, and to systematically excoriate those who criticise or dissent from mandatory vaccine programs, function as a corrupting process and, by extension, serve to provoke the notion that corruption does indeed exist within the state-pharma alliance.

Strong community engagement has been critical to support COVID-19 vaccine uptake in Australia and elsewhere. Community engagement builds trust, enables tailored information dissemination and shapes social norms. Engagement is particularly important in communities with greater vaccine hesitancy, lower health literacy and mistrust in authorities. Early in 2021, as a team of vaccine social scientists and clinicians, we developed a program to train and empower community, faith, industry and healthcare leaders to advocate for COVID-19 vaccines as “vaccine champions”. We partnered with the Victorian Department of Health to deliver 91 online Vaccine Champions sessions from March 2021 to June 2022. Over 80 people who received this training were supported by the Department of Health to become formal vaccine champions, independently delivering over 100 locally tailored information sessions. Our survey evaluation of 20 sessions delivered in 2022 found most participants (94%, 118/125) felt more confident to discuss safety and effectiveness of COVID-19 vaccines and find relevant information after attending a session. We also recorded >90% participant satisfaction with training content, format and presentation. Qualitative feedback from two group interviews highlighted the value of vaccine communication role plays and opportunities for discussion. In this brief report, we present an overview of the Vaccine Champions program, evaluation and next steps.

Ticks are worldwide ectoparasites to humans and animals, and are associated with numerous health and economic effects. Threatening over 80% of the global cattle population, tick and tick-borne diseases (TTBDs) particularly constrain livestock production in the East, Central and Southern Africa. This, therefore, makes their control critical to the sustainability of the animal industry in the region. Since ticks are developing resistance against acaricides, anti-tick vaccines (ATVs) have been proposed as an environmentally friendly control alternative. Whereas they have been used in Latin America and Australia to reduce tick populations, pathogenic infections and number of acaricide treatments, commercially registered ATVs have not been adopted in tropical Africa for tick control. This is majorly due to their limited protection against economically important tick species of Africa and lack of research. Recent advances in various omics technologies and reverse vaccinology have enabled the identification of many candidate anti-tick antigens (ATAs), and are likely to usher in the next generation of vaccines, for which Africa should prepare to embrace. Herein, we highlight some scientific principles and approaches that have been used to identify ATAs, outline characteristics of a desirable ATA for vaccine design and propose the need for African governments to investment in ATV research to develop vaccines relevant to local tick species (personalized vaccines). We have also discussed the prospect of incorporating anti-tick vaccines into the integrated TTBDs control strategies in the sub-Saharan Africa, citing the case of Uganda.

Research within the health and welfare program of the Cooperative Research Centre for Cattle and Beef Quality has delivered important improvements to the Australian cattle industry. Vaccines to assist with the control of bovine respiratory disease were developed and commercialised from Australian isolates of Mannheimia haemolytica and pestivirus (mucosal disease). Our understanding of the benefits of weaning cattle by confinement and hand feeding in yards (yard weaning) has been consolidated, and yard weaning has been adopted as ‘best practice’ for cattle production in the temperate zones of Australia. The importance of good temperament for improved growth rates and reduced morbidity during feedlot finishing, and for adaptation to stressors such as road transport, has been demonstrated. In response to this knowledge, industry is increasingly measuring flight time for use in breeding programs and feedlot management. The risk to meat quality of stressors such as mixing unfamiliar cattle in the weeks preceding slaughter or acute stress in the last 15 min before slaughter has been described. Adoption of these findings through Quality Assurance schemes will assist in assurance for the community and for export markets of the welfare standards of the Australian cattle and beef industry. This review provides details of the experiments that led to these achievements and to some improved understandings of temperament and behaviour of beef cattle.

Clostridium perfringens, a spore-forming, Gram-positive, anaerobic bacterium, causes a variety of diseases throughout the animal kingdom. Each disease in each animal species tends to be caused by particular strains of C. perfringens and is defined by the tissue tropism and toxin profile of the bacteria. In chickens toxinotype A strains cause necrotic enteritis; a disease characterised by tissue damage to the proximal regions of the small intestine. In extreme cases the disease can be lethal but is more commonly seen as a sub-clinical disease that causes welfare issues and productivity losses within the poultry industry. The disease is currently well controlled in Australia by good management practices and, for some poultry producers, the use of antibiotics in the feed. However, the disease does cause significant issues in other regions including North America and Europe. In Europe there was a spike of necrotic enteritis disease when antibiotics were withdrawn from animal feeds. It is probable that the disease will become more of an issue in the Australian poultry industry as in-feed antibiotic use is reduced. Therefore, other methods of disease control are under investigation, including the development of vaccines.

The Cooperative Research Centre for the Cattle and Beef Industry (Meat Quality) was formulated in 1992 by CSIRO, the University of New England (UNE), NSW Agriculture and Queensland Department of Primary Industries (QDPI) to address the emerging beef quality issue facing the Australian beef industry at that time: the demand from domestic and export consumers for beef of consistent eating quality. An integrated program of research involving meat science, molecular and quantitative genetics and growth and nutrition was developed. To meet the expectations of the Commonwealth of Australia, additional projects dealing with animal health and welfare and environmental waste generated by feedlot cattle were included. The program targeted both grain- and grass-finished cattle from temperate and tropical Australian environments. Integration of research on this scale could not have been achieved by any of the participating institutions working alone. This paper describes the financial and physical resources needed to implement the program and the management expertise necessary for its completion. The experience of developing and running the Cooperative Research Centre confirms the complexity and cost of taking large numbers of pedigreed cattle through to carcass and meat quality evaluation. Because of the need to capture the commercial value of the carcass, it was necessary to work within the commercial abattoir system. During the life of the Cooperative Research Centre, abattoir closure and/or their willingness to tolerate the Research Centre’s experimental requirements saw the Cooperative Research Centre operations move to 6 different abattoirs in 2 states, each time losing some precision and considerable revenue. This type of constraint explains why bovine meat science investigations on this scale have not previously been attempted. The Cooperative Research Centre project demonstrates the importance of generous industry participation, particularly in cattle breeding initiatives. Such involvement, together with the leadership provided by an industry-driven Board guarantees early uptake of results by beef industry end-users. The Cooperative Research Centre results now provide the blueprint for genetic improvement of beef quality traits in Australian cattle herds. Heritabilities of beef tenderness, eating quality, marbling, fatness and retail beef yields are now recorded. Genetic correlations between these traits and growth traits are also available. Outstanding sires for beef quality have been identified. Linked genetic markers for some traits have been described and commercialised. Non-genetic effects on beef quality have been quantified. Australian vaccines against bovine respiratory disease have been developed and commercialised, leading to a reduction in antibiotic use and better cattle performance. Sustainable re-use of feedlot waste has been devised.

The SARS-CoV-2 pandemic created challenges for the oil and gas industry. Qatar experienced three significant waves during the pandemic that disproportionately affected the workers in shared accommodation. In Australia, the public health measures limited the spread of SARS-CoV-2 in the industry until the Omicron wave. Anti-SARS-CoV-2 seropositivity was assessed in five oil and gas subcontractors and five hospital subcontractors in Qatar between 21 June and 9 September 2020. Vaccine effectiveness was assessed in Qatar. Vaccine effectiveness in an LNG tanker crew off Gladstone was calculated. The initial study in Qatar included 4970 craft manual workers (CMWs) who were mostly men (95.0%). Infection positivity (antibody and/or polymerase chain reaction (PCR) positive) ranged from 62.5% (95% CI: 58.3–66.7%) to 83.8% (95% CI: 79.1–87.7%). Only five infections were severe and one was critical – an infection severity rate of 0.2% (95% CI: 0.1–0.4%). Rapid antibody tests (RATs) were effective in diagnosis of the SARS-CoV-2 virus infections. Vaccine effectiveness against severe, critical or fatal infections were above 90% in both the Qatar and Australian studies, but protection against infection waned significantly after 6 months. In Qatar and Australia, the industry implemented effective control measures including the use of RATs, PCR tests, test, trace, isolation, quarantine (TTIQ) and vaccination. In both countries, the LNG industry collaborated with public health experts and other experts and was involved in research to assess and manage the risk of COVID-19. Production of LNG was not affected. Participation in public health research in both countries contributed to important scientific publications and protected the industry. COVID-19 may become endemic.

Erysipelothrix rhusiopathiae is a bacterial pathogen that is the causative agent of erysipelas in a variety of animals, including swine, emus, turkeys, muskox, caribou, moose, and humans. This study aims to investigate the population structure and genomic features of Australian isolates of E. rhusiopathiae in the Australian pig industry and compare them to the broader scope of isolates worldwide. A total of 178 isolates (154 Australian, seven vaccine isolates, six international isolates, and 11 of unknown origin) in this study were screened against an MLST scheme and publicly available reference isolates, identifying 59 new alleles, with isolates separating into two main single locus variant groups. Investigation with BLASTn revealed the presence of the spaA gene in 171 (96%) of the isolates, with three main groups of SpaA protein sequences observed amongst the isolates. Novel SpaA protein sequences, categorised here as group 3 sequences, consisted of two sequence types forming separate clades to groups 1 and 2, with amino acid variants at positions 195 (D/A), 303 (G/E) and 323(P/L). In addition to the newly identified groups, five new variant positions were identified, 124 (S/N), 307 (Q/R), 323 (P/L), 379 (M/I), and 400 (V/I). Resistance screening identified genes related to lincomycin, streptomycin, erythromycin, and tetracycline resistance. Of the 29 isolates carrying these resistance genes, 82% belonged to SpaA group 2-N101S (n = 22) or 2-N101S-I257L (n = 2). In addition, 79% (n = 23) of these 29 isolates belonged to MLST group ST 5. Our results illustrate that Australia appears to have a unique diversity of E. rhusiopathiae isolates in pig production industries within the wider global context of isolates.

ABSTRACTViruses exploit molecules on the target membrane as receptors for attachment and entry into host cells. Thus, receptor expression patterns can define viral tissue tropism and might to some extent predict the susceptibility of a host to a particular virus. Previously, others and we have shown that respiratory pathogens of the genusGammacoronavirus, including chicken infectious bronchitis virus (IBV), require specific α2,3-linked sialylated glycans for attachment and entry. Here, we studied determinants of binding of enterotropic avian gammacoronaviruses, including turkey coronavirus (TCoV), guineafowl coronavirus (GfCoV), and quail coronavirus (QCoV), which are evolutionarily distant from respiratory avian coronaviruses based on the viral attachment protein spike (S1). We profiled the binding of recombinantly expressed S1 proteins of TCoV, GfCoV, and QCoV to tissues of their respective hosts. Protein histochemistry showed that the tissue binding specificity of S1 proteins of turkey, quail, and guineafowl CoVs was limited to intestinal tissues of each particular host, in accordance with the reported pathogenicity of these virusesin vivo. Glycan array analyses revealed that, in contrast to the S1 protein of IBV, S1 proteins of enteric gammacoronaviruses recognize a unique set of nonsialylated type 2 poly-N-acetyl-lactosamines. Lectin histochemistry as well as tissue binding patterns of TCoV S1 further indicated that these complex N-glycans are prominently expressed on the intestinal tract of various avian species. In conclusion, our data demonstrate not only that enteric gammacoronaviruses recognize a novel glycan receptor but also that enterotropism may be correlated with the high specificity of spike proteins for such glycans expressed in the intestines of the avian host.IMPORTANCEAvian coronaviruses are economically important viruses for the poultry industry. While infectious bronchitis virus (IBV), a respiratory pathogen of chickens, is rather well known, other viruses of the genusGammacoronavirus, including those causing enteric disease, are hardly studied. In turkey, guineafowl, and quail, coronaviruses have been reported to be the major causative agent of enteric diseases. Specifically, turkey coronavirus outbreaks have been reported in North America, Europe, and Australia for several decades. Recently, a gammacoronavirus was isolated from guineafowl with fulminating disease. To date, it is not clear why these avian coronaviruses are enteropathogenic, whereas other closely related avian coronaviruses like IBV cause respiratory disease. A comprehensive understanding of the tropism and pathogenicity of these viruses explained by their receptor specificity and receptor expression on tissues was therefore needed. Here, we identify a novel glycan receptor for enteric avian coronaviruses, which will further support the development of vaccines.

COVID-19 pandemic has affected people’s daily life dramatically since December 2019. More than 211 million cases and 4.42 million deaths have been reported and confirmed all over the world. Long-term care facilities are taking the biggest hit during this pandemic, even after the spread-out of the vaccines. Globally, residents in long-term care facilities have experienced disproportionately high morbidity and mortality from COVID-19. Elderlies residing in long-term care facilities have the greatest susceptibility to COVID-19 and the poorest outcomes from infections. This chapter overviewed the insight, impact, and challenges of COVID-19 on the residential care homes in UK, US, and Australia and provided possible implications for the long-term care market post-pandemic.